{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:02:20Z","timestamp":1789984940481,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1124\/dmd.112.049114","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T05:11:27Z","timestamp":1352178687000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes"],"prefix":"10.1016","volume":"41","author":[{"given":"Jialin","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzhou","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.049114_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/DMDI.2011.031","article-title":"Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development","volume":"26","author":"Boulenc","year":"2011","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1124\/dmd.112.049114_bib2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1124\/dmd.111.040634","article-title":"Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions","volume":"39","author":"Chen","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib3","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1124\/dmd.109.027029","article-title":"In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of America perspective","volume":"37","author":"Chu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib4","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.112.049114_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2012.06.043","article-title":"Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design","author":"Di","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1124\/dmd.112.049114_bib6","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1002\/jps.22674","article-title":"Development of a new permeability assay using low-efflux MDCKII cells","volume":"100","author":"Di","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.112.049114_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.049114_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib9","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp population-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.112.049114_bib12","series-title":"17th North American Regional ISSX Meeting;","article-title":"Identification of the human enzymes involved in the oxidative metabolism of crizotinib","author":"Johnson","year":"2011"},{"key":"10.1124\/dmd.112.049114_bib13","series-title":"17th North American Regional ISSX Meeting;","article-title":"Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects,","author":"Johnson","year":"2011"},{"key":"10.1124\/dmd.112.049114_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00003088-200645050-00006","article-title":"A novel strategy for physiologically based predictions of human pharmacokinetics","volume":"45","author":"Jones","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.112.049114_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1007572803027","article-title":"Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4","volume":"17","author":"Kanamitsu","year":"2000","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.112.049114_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/00498250701534885","article-title":"Challenges and opportunities with modelling and simulation in drug discovery and drug development","volume":"37","author":"Lav\u00e9","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.112.049114_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.110.036400","article-title":"Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma","volume":"39","author":"Mao","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/dmd.111.043158","article-title":"Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions","volume":"40","author":"Mao","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17425255.3.2.235","article-title":"Whole-body physiologically based pharmacokinetic models","volume":"3","author":"Nestorov","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.112.049114_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.049114_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib24","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.112.049114_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u2018In silico\u2019 simulations to assess the \u2018in vivo\u2019 consequences of \u2018in vitro\u2019 metabolic drug\u2013drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.112.049114_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.112.049114_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.112.049114_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/106002809502900612","article-title":"Recent advances: the cytochrome P450 enzymes","volume":"29","author":"Slaughter","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.112.049114_bib29","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1124\/dmd.108.025494","article-title":"Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator","volume":"37","author":"Xu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/dmd.110.035857","article-title":"Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model","volume":"39","author":"Yamazaki","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.049114_bib32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":"Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.112.049114_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/17425255.4.2.151","article-title":"The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo","volume":"4","author":"Zhao","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.112.049114_bib34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.104.002832","article-title":"Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes","volume":"33","author":"Zhao","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.049114_bib35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1124\/dmd.110.037911","article-title":"CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs","volume":"39","author":"Zimmerlin","year":"2011","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624116108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624116108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.049114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:41:22Z","timestamp":1739907682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624116108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0090955624116108"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.049114","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.049114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}